AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32606899
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (LICUS)
Trial: 32606903
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg nalbuphine with 12.5 mg hyperbaric bupivacaine
Trial: 32606903
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg midazolam with 12.5 mg hyperbaric bupivacaine
Trial: 32606903
Drug: 12.5 mg
RxNorm normalized name: rutin 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5 mg hyperbaric bupivacaine plus 0.5 mL saline (Control)
Trial: 32606902
Drug: Lidocaine topical
RxNorm normalized name: lidocaine topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine topical system 1.8% under heat conditions
Trial: 32606902
Drug: Lidocaine topical
RxNorm normalized name: lidocaine topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine topical system 1.8% under exercise conditions
Trial: 32606902
Drug: Lidocaine topical
RxNorm normalized name: lidocaine topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine topical system 1.8% under all conditions
Trial: 32606956
Drug: Icotinib (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Icotinib (125 mg 3 times per day)
Trial: 32606956
Drug: Placebo (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (125 mg 3 times per day)
Trial: 32607502
Drug: Enhanced standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced standard of care (facilitating referral to a local substance use treatment clinic)
Trial: 32607929
Drug: Simple Segmentation
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simple Segmentation Tool (SST) administered by physicians and nurses
Trial: 32611662
Drug: Adverse drug
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adverse drug reactions in patients with CKD
Trial: 32611662
Drug: Specific pharmacologic
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific pharmacologic classes (antithrombotic agents)
Trial: 32611728
Drug: Lower dose
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower dose of alteplase
Trial: 32611728
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose of alteplase
Trial: 32611729
Drug: Dynamic contrast-enhanced
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dynamic contrast-enhanced MRI (DCE-MRI) before and 6 months after endovascular treatment
Trial: 32611739
Drug: Therapy-naïve patients
RxNorm normalized name: lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Therapy-naïve patients receiving standard PIBD care with follow-up up to 20 years.
Trial: 32613089
Drug: Low-dose lung
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose lung irradiation (LD-RT) combined with pharmacological treatment
Trial: 32613089
Drug: Low-dose lung
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose lung irradiation (LD-RT)
Trial: 32613402
Drug: Experimental formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental formula with high beta-PA (20-25%) from cow's milk fat and 0.5 g GOS/100 ml
Trial: 32614327
Drug: Triaxial accelerometer
RxNorm normalized name: triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triaxial accelerometer sensor placed on the anterior chest to monitor body positions 24-hours daily through a 4-week monitoring period.
Trial: 36803645
Drug: Pyrotinib monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrotinib monotherapy
Trial: 32614702
Drug: Non-docetaxel-based chemotherapy
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Non-docetaxel-based chemotherapy
Trial: 32614963
Drug: Treatment-free remission
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-free remission (TFR) after stopping tyrosine kinase inhibitors (TKIs)
Trial: 32615108
Drug: Avapritinib (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avapritinib (300 mg recommended phase 2 dose, administered orally once daily)
Trial: 32615108
Drug: Avapritinib (varied
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avapritinib (varied doses from 30 mg to 600 mg)
Trial: 32615108
Drug: Avapritinib (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avapritinib (600 mg)
Trial: 32615108
Drug: Maximum tolerated
RxNorm normalized name: Maximum-H
DrugBank: Hydrocortisone (DB00741)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Maximum tolerated dose of Avapritinib
Trial: 32615108
Drug: Recommended phase
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recommended phase 2 dose of Avapritinib
Trial: 32615331
Drug: Nerindocianine sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nerindocianine sodium (0.06 mg/kg, 0.12 mg/kg, 0.045 mg/kg)
Trial: 32615331
Drug: Nerindocianine sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nerindocianine sodium (0.06 mg/kg)
Trial: 32615649
Drug: Diabetic patients
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diabetic patients on insulin
Trial: 32615649
Drug: Diabetic patients
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diabetic patients not on insulin
Trial: 32615649
Drug: Non-diabetic patients
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-diabetic patients with pre-operative HbA1c < 42 mmol/mol and random plasma glucose < 7.8 mmol/l
Trial: 32616009
Drug: Lipid-based Nutrient
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-based Nutrient Supplement (LNS)
Trial: 32616515
Drug: Topical ASN008
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ASN008 gel
Trial: 32616515
Drug: Topical ASN008
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ASN008 gel (once-daily application for 5 days)
Trial: 32616555
Drug: Enzalutamide plus
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enzalutamide plus pembrolizumab (200 mg IV every 3 weeks for four doses)
Trial: 32616557
Drug: Lutathera 3.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lutathera 3.7 GBq every 8 weeks for four doses with nivolumab 240 mg every 2 weeks
Trial: 32616557
Drug: Lutathera 7.4
RxNorm normalized name: Lutathera 7.4 GBq per 25 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lutathera 7.4 GBq every 8 weeks for four doses with nivolumab 240 mg every 2 weeks
Trial: 32616759
Drug: Single infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single infusion of autologous umbilical cord blood
Trial: 32616867
Drug: Ranibizumab treatment
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab treatment (three monthly injections followed by PRN regimen)
Trial: 32617173
Drug: mHealth intervention
RxNorm normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mHealth intervention designed for psychiatric PTSD patients as a therapy add-on
Trial: 32617429
Drug: Virtual reality
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual reality (VR) targeting sitting balance for 30-45 min daily for 10-12 sessions
Trial: 32617429
Drug: Virtual reality
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual reality (VR) with limited arm movement for 30-45 min daily for 10-12 sessions
Trial: 32617435
Drug: Body therapy
RxNorm normalized name: Keri Whole Body Therapy Original
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Body therapy treatment as add-on to treatment as usual
Trial: 32617453
Drug: Multistrain probiotic
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multistrain probiotic (4 capsules of Vivomixx)
Trial: 32617528
Drug: Opt-In Treatment
RxNorm normalized name: Glau-Opt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opt-In Treatment Approach
Trial: 32617528
Drug: Opt-Out Treatment
RxNorm normalized name: Cough Out
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Opt-Out Treatment Approach
Trial: 32617582
Drug: Rituximab (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (1 g each, two courses, 2 weeks apart at the beginning and again at 6 months)
Trial: 32617919
Drug: ORBERA® Intragastric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ORBERA® Intragastric Balloon System (IGB) as an adjunct to lifestyle intervention
Trial: 32618884
Drug: empagliflozin 10 mg
RxNorm normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: empagliflozin 10 mg or 25 mg
Trial: 32619077
Drug: Ribociclib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribociclib plus letrozole (600 mg for Asian non-Japanese patients; 300 mg for Japanese patients)
Trial: 32619077
Drug: Ribociclib combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribociclib combined with endocrine therapy
Trial: 32619115
Drug: Blinatumomab, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blinatumomab, a CD19 BiTE, administered to adults with MRD BCP-ALL after chemotherapy.
Trial: 32622884
Drug: Futibatinib 20
RxNorm normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Futibatinib 20 mg q.d.
Trial: 32622884
Drug: Futibatinib 8-200
RxNorm normalized name: Futibatinib
DrugBank: Futibatinib (DB15149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Futibatinib 8-200 mg t.i.w. or 4-24 mg q.d.
Trial: 32624195
Drug: Sofosbuvir monotherapy
RxNorm normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sofosbuvir monotherapy
Trial: 32624280
Drug: Bipolar androgen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bipolar androgen therapy (BAT) with 400 mg testosterone cypionate intramuscularly every 28 days
Trial: 38167882
Drug: Bipolar androgen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bipolar androgen therapy (BAT)
Trial: 32624280
Drug: Bipolar androgen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bipolar androgen therapy (BAT) followed by AR-targeted therapy rechallenge
Trial: 32627114
Drug: Sirolimus-coated balloon
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus-coated balloon (SCB) treatment at the graft vein junction after successful percutaneous thrombectomy.
Trial: 32627589
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of recruitment strategies
Trial: 32628583
Drug: Docetaxel given
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel given every 3 weeks for 4 cycles plus subcutaneous trastuzumab
Trial: 32628583
Drug: Docetaxel and
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel and subcutaneous trastuzumab
Trial: 32631491
Drug: UGN-101 (mitomycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UGN-101 (mitomycin 4 mg per mL; maximum 60 mg per instillation) administered via retrograde catheter to the renal pelvis and calyces, with six instillations once weekly.
Trial: 32631787
Drug: Capecitabine with
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine with Aflibercept (Arm A, starting dose 1100 mg/m²)
Trial: 32631787
Drug: Capecitabine with
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine with Aflibercept (recommended dose for phase II trials established at 1300 mg/m²)
Trial: 32631788
Drug: Panitumumab 6
RxNorm normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Panitumumab 6 mg/kg every 2 weeks until progression or unacceptable toxicity
Trial: 32633563
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of talimogene laherparepvec with atezolizumab
Trial: 32634122
Drug: Detection of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detection of IgM and IgG anti-CD4+ cell antibodies
Trial: 32634234
Drug: Sonidegib 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sonidegib 400 mg daily + ruxolitinib 20 mg twice daily
Trial: 32634238
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of cord donor leukocyte infusion (cDLI) posttransplant.
Trial: 32634435
Drug: Histamine-receptor antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histamine-receptor antagonist intake (hazard ratio)
Trial: 32634435
Drug: Antibiotic prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic prophylaxis (hazard ratio)
Trial: 32634610
Drug: Osimertinib 160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osimertinib 160 mg
Trial: 32634611
Drug: Trastuzumab emtansine
RxNorm normalized name: Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab emtansine (T-DM1) 3.6 mg/kg every 3 weeks (intravenously) until unacceptable toxicity, withdrawal of consent, or disease progression
Trial: 32636771
Drug: Antipsychotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic treatment for 1 year
Trial: 38383268
Drug: Low-pressure hyperbaric
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-pressure hyperbaric oxygen therapy (HBOT)
Trial: 32637723
Drug: Intensive non-surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive non-surgical treatment starting with an eight-week low-calorie diet
Trial: 34277393
Drug: Neoadjuvant Chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant Chemotherapy (NCT)
Trial: 32638247
Drug: Evaluation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evaluation of 25(OH)D threshold for maximal suppression of parathyroid hormone (PTH)
Trial: 32639484
Drug: Intensive speech
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive speech treatment targeting voice (16 1-hour sessions/1 month)
Trial: 32639484
Drug: Intensive speech
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive speech treatment targeting articulation (16 1-hour sessions/1 month)
Trial: 32641071
Drug: Patisiran (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patisiran (0.3 mg/kg intravenously every 3 weeks)
Trial: 32641131
Drug: 0.02% polihexanide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.02% polihexanide solution used for catheter irrigation on five consecutive days
Trial: 32641261
Drug: Nivolumab 240
RxNorm normalized name: nivolumab 240 MG in 24 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 240 mg every 2 weeks (Q2W) for ≤ 24 months or until confirmed progression/unacceptable toxicity
Trial: 32718906
Drug: Nivolumab 240
RxNorm normalized name: nivolumab 240 MG in 24 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 240 mg every 2 weeks (Q2W)
Trial: 32642592
Drug: Fuzheng Huayu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fuzheng Huayu (FZHY) tablets and entecavir
Trial: 32643995
Drug: Ketamine infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine infusions (6 infusions over 2 weeks)
Trial: 32645016
Drug: Fadraciclib (CYC065)
RxNorm normalized name: Samuraciclib
DrugBank: Samuraciclib (DB16061)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fadraciclib (CYC065) in combination with BCL2 inhibitors (e.g., venetoclax)
Trial: 32645153
Drug: Inhibitors of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhibitors of the renin-angiotensin-aldosterone system
Trial: 32645282
Drug: Cabozantinib 60
RxNorm normalized name: cabozantinib 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib 60 mg orally once daily in 28-day cycles until disease progression or unacceptable toxicity
Trial: 32645640
Drug: Ocrelizumab (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ocrelizumab (600 mg treatment cycles at week 0, 24, 48, 72)
Trial: 32645640
Drug: Ocrelizumab (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ocrelizumab (600 mg treatment cycles)
Trial: 32647531
Drug: Apple extract
RxNorm normalized name: apple extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apple extract (AE, 2.0 g)
Trial: 32647531
Drug: Mulberry fruit
RxNorm normalized name: MULBERRY
DrugBank: Broussonetia papyrifera pollen (DB10736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mulberry fruit extract (MFE, 1.5 g)
Trial: 32647531
Drug: Mulberry leaf
RxNorm normalized name: MULBERRY
DrugBank: Broussonetia papyrifera pollen (DB10736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mulberry leaf extract (MLE, 1.0 g)
Trial: 32647531
Drug: Elderberry extract
RxNorm normalized name: elderberry extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elderberry extract (EE, 2.0 g)
Trial: 32647531
Drug: Turmeric extract
RxNorm normalized name: Turmeric Extract
DrugBank: Turmeric (DB14276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Turmeric extract (TE, 0.18 g)
Trial: 32647531
Drug: White bean
RxNorm normalized name: White bean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White bean extract (WBE, 3.0 g)
Trial: 32647531
Drug: Control (rice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (rice porridge with ~50 g available carbohydrate)
Trial: 32647975
Drug: Etelcalcetide (0.035
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etelcalcetide (0.035 mg/kg intravenously)
Trial: 32648303
Drug: 500-mg ivosidenib
RxNorm normalized name: ivosidenib
DrugBank: Ivosidenib (DB14568)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500-mg ivosidenib in participants with mild hepatic impairment
Trial: 32649004
Drug: Neoadjuvant bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Neoadjuvant bevacizumab (5 mg/kg) with modified FOLFOX7 (oxaliplatin 85 mg/m2) for six cycles
Trial: 32649037
Drug: Supersaturated oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supersaturated oxygen (SSO) therapy for 60 minutes
Trial: 32650731
Drug: CAIDE85+ study
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CAIDE85+ study intervention including cognitive evaluations (CERAD, Trail Making Test-A, Letter-Digit Substitution Test, Clinical Dementia Rating, Activities of Daily Living) and assessments of physical health status, psychosocial wellbeing, and blood biomarkers relevant for dementia and ageing.
Trial: 32650734
Drug: General medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General medicine with acute bacterial infections
Trial: 32651887
Drug: Extended release
RxNorm normalized name: Tylenol Extended Release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended release naltrexone treatment starting in the week prior to release from prison
Trial: 32651996
Drug: Antithrombotic therapies
RxNorm normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithrombotic therapies prescribed after percutaneous coronary intervention
Trial: 32652442
Drug: Pamiparib (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamiparib (3 mg/kg)
Trial: 32652442
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Pamiparib with Temozolomide (TMZ)
Trial: 32653053
Drug: Margetuximab 15
RxNorm normalized name: Margetuximab
DrugBank: Margetuximab (DB14967)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Margetuximab 15 mg/kg plus pembrolizumab 200 mg intravenously every 3 weeks (recommended phase 2 dose)
Trial: 32653053
Drug: Margetuximab 10
RxNorm normalized name: Margetuximab
DrugBank: Margetuximab (DB14967)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Margetuximab 10 mg/kg plus pembrolizumab 200 mg intravenously every 3 weeks (dose-escalation phase)
Trial: 32653622
Drug: Ixazomib (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixazomib (4 mg, oral, weekly for 4 doses from days +60 to +90)
Trial: 32655854
Drug: Low-dose scopolamine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose scopolamine